Evidence map›Paper›PMID 34646432›Full record

ArticleTherapeutic advances in hematology2021

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.

Monica Carpenedo, Erminia Baldacci, Claudia Baratè, Alessandra Borchiellini, Francesco Buccisano, Giuseppina Calvaruso, Federico Chiurazzi, Bruno Fattizzo, Gaetano Giuffrida, Elena Rossi and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 15 institutions in 1 country.

Monica CarpenedoHematology and Transplantation Unit, ASST San Gerardo Hospital, Via G. B. Pergolesi, 33, 20900 Monza MB, Italy.ORCID https://orcid.org/0000-0002-4355-3954
Erminia BaldacciDepartment of Hematology, Policlinico Umberto I University Hospital, Rome, Italy.
Claudia BaratèHematology and Bone Marrow Transplant Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Alessandra BorchielliniRegional Reference Center of Haemostasis and Thrombosis Haematology Unit, Città della Salute e della Scienza, Turin, Italy.
Francesco BuccisanoHematology, Department of BioMedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Giuseppina CalvarusoCampus of Hematology Franco and Piera Cutino, AOOR Villa Sofia-V. Cervello, Palermo, Italy.
Federico ChiurazziDepartment of Clinical Medicine, University "Federico II" of Naples, Naples, Italy.
Bruno FattizzoUOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Gaetano GiuffridaDivision of Haematology, A.O.U. Policlinico Vittorio Emanuele, Catania, Italy.
Elena RossiDepartment of Radiological and Hematological Sciences, Universita Cattolica del Sacro Cuore and Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Francesca PalandriIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Potito Rosario ScalzulliDepartment of Hematology and Stem Cell Transplant Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy.
Sergio Mario SiragusaDepartment PROMISE, University of Palermo, Palermo, Italy.
Angelantonio VitucciHaematology with Transplant Unit, Az. Universitario-Ospedaliera Consorziale Policlinico, Bari, Italy.
Francesco ZajaDepartment of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliera San Gerardo · ITAzienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele · ITAzienda Universitaria Ospedaliera Consorziale - Policlinico Bari · ITCasa Sollievo della Sofferenza · ITIstituto di Ematologia di Bologna · ITOspedale Vincenzo Cervello · ITPoliclinico Umberto I · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Milan · ITUniversity of Naples Federico II · ITUniversity of Palermo · ITUniversity of Pisa · ITUniversity of Rome Tor Vergata · ITUniversity of Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn patients with primary immune thrombocytopenia (ITP), a short course of steroids is routinely given as first-line therapy. However, the response is often transient and additional therapy is usually needed. Thrombopoietin receptor agonists (TPO-RAs) are frequently used as second-line therapy, although there is little clinical guidance on the timing of their administration and on tapering/discontinuation of the drug. To provide clinical recommendations, we used the Delphi technique to obtain consensus for statements regarding administration and on tapering/discontinuation of second-line TPO-RAs among a group of Italian clinicians with expertise in management of ITP.

methodsThe Delphi process was used to obtain agreement on five statements regarding initiation and on tapering/discontinuation of second-line TPO-RAs. Agreement was considered when 75% of participants approved the statement. Eleven experts participated in the voting.

resultsFull consensus was reached for three of the five statements. The experts held that an early switch from corticosteroids to a TPO-RA has the dual advantage of sparing patients from corticosteroid abuse and improve long-term clinical outcomes. All felt that dose reduction of TPO-RAs can be considered in patients with a stable response and platelet count >100 × 10

conclusionThe present consensus can help to provide guidance on use of TPO-RAs in daily practice in patients with ITP. PLAIN LANGUAGE SUMMARY:

Indexed as

consensusDelphiimmune thrombocytopeniamanagementsecond linetherapythrombopoietin receptor agonists

Identifiers

PMID34646432
PMCPMC8504223
OpenAlexW3207464851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.